SYK · Earnings call · 2026Q3T · Full report

Guidance / Outlook

STRYKER CORP · 2026-10-29 · Importance 69 · Surprise 60 · In source text

Stryker expects Q4 organic sales growth to be similar to Q3, assuming continuation of the observed procedure environment and continued strong capital demand. For full-year 2026, management revised organic net sales growth guidance to 6.5%–7% and adjusted net earnings per share guidance to $14.80–$14.90, citing softer hip and knee procedure trends, lingering Peripheral Vascular supply constraints, and mitigation of execution risk on capital equipment sales. For 2027, the company is not providing formal guidance until early next year, but expects to grow at the high end of its markets. Management says it is monitoring market conditions, procedure volumes, and the broader macroeconomic environment as it finalizes the 2027 forecast.

Key facts

• Stryker expected full-year 2026 adjusted other income and expense of approximately $400 million.
• Stryker revised full-year 2026 adjusted net EPS guidance to $14.80–$14.90.
• Stryker's Q4 2026 organic sales growth outlook anticipated a similar overall rate to Q3, assuming continuation of the observed procedure environment and continued strong capital demand.
• Stryker expected its full-year 2026 effective tax rate to be 15.5% to 16%.
• Stryker revised full-year 2026 organic net sales growth guidance to 6.5%–7%.
• Spencer Stiles was appointed Stryker's next CEO after spending nearly 3 decades at Stryker.
• Stryker said it was assuming the hip and knee market would remain at its current level in its guidance rather than counting on a snapback.
• Stryker expected strong Trauma and Extremities growth in Q4 2026.

Impact estimates